Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03268122 · ClinicalTrials.gov registry record · NA
Comparison of Standard Isolation With Targeted Isolation for Preventing Nosocomial Transmission of MRSA and VRE
A NA study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 1,974
- Enrollment target
NCT03268122 is a NA study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 1,974 participants.
The verdict
NCT03268122, a NA study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,974 participants
- Enrollment target
Study Summary
Hospital-acquired infections are common and frequently lead to poor outcomes, including death, in affected patients. Two common organisms that cause infections in the hospital are methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). One strategy used to prevent these infections is contact isolation of hospitalized patients with MRSA and/or VRE. It is unclear whether contact isolation decreases the rate of infection with MRSA and/or VRE. The CONTACT-PILOT study is designed to test the hypothesis that contact isolation decreases the rate of infection with MRSA and/or VRE in patients in the intensive care unit (ICU). The study will enroll all adults in the Medical ICU and will run between September 2017 and April 2018. During some months, all patients in the Medical ICU patients will be placed in isolation for MRSA or VRE if they have a current infection or colonization with either organism, or a recent history thereof. During other months, patients will only be placed in isolation for MRSA or VRE if they have an active, highly-transmissible infection with either organism, such as a pneumonia or an open, draining wound.
Interventions
- OTHER Standard Contact Isolation
- OTHER Targeted Contact Isolation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,974 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2018-05-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03268122
The ClinicalTrials.gov registry entry for NCT03268122 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,974 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard Contact Isolation is the first listed.
NCT03268122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03268122 about?
NCT03268122 is a clinical study titled "Comparison of Standard Isolation With Targeted Isolation for Preventing Nosocomial Transmission of MRSA and VRE". Hospital-acquired infections are common and frequently lead to poor outcomes, including death, in affected patients. Two common organisms that cause infections in the hospital are methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). One strategy used to pre...
What is the current status of trial NCT03268122?
This trial is currently completed. It is a NA study. The enrollment target is 1,974 participants. The study started on 2017-09-01. Estimated completion is 2018-05-30.
What interventions are being tested in trial NCT03268122?
The interventions under investigation include: Standard Contact Isolation (OTHER), Targeted Contact Isolation (OTHER).
Who is sponsoring clinical trial NCT03268122?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.